Search research articles
Contact Us
Filters
Showing results (201-210 of 265) with videos related to
Page
of 27
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 24, 2014
A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma
Wolfgang Wick, Harald Fricke, Klaus Junge, et al.
Acta Neuropathologica
|
January 28, 2014
Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms
David E Reuss, Antje Habel, Christian Hagenlocher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2009
Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network
Michael Weller, Jörg Felsberg, Christian Hartmann, et al.
Neuro-Oncology
|
March 24, 2009
Characterization of novel and complex genomic aberrations in glioblastoma using a 32K BAC array
Helena Nord, Christian Hartmann, Robin Andersson, et al.
Neuro-Oncology
|
July 17, 2014
Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial
Benedikt Wiestler, David Capper, Volker Hovestadt, et al.
Cancer Research
|
April 3, 2003
Gene expression-based classification of malignant gliomas correlates better with survival than histological classification
Catherine L Nutt, D R Mani, Rebecca A Betensky, et al.
Clinical Neuropathology
|
March 31, 2023
Update on quality assurance in neuropathology: Summary of the round robin trials on <i>TERT</i> promoter mutation, <i>H3-3A</i> mutation, 1p/19q codeletion, and <i>KIAA1549::BRAF</i> fusion testing in Germany in 2020 and 2021
Sandra Pohl, Lora Dimitrova, Maja Grassow-Narlik, et al.
Acta Neuropathologica
|
May 13, 2015
IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO
David E Reuss, Yasin Mamatjan, Daniel Schrimpf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2009
Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival
Aurélie Ernst, Stefanie Hofmann, Rezvan Ahmadi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 11, 2009
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide
Wolfgang Wick, Christian Hartmann, Corinna Engel, et al.
Page
of 27
Search research articles
Search
Showing results (201-210 of 265) with videos related to
Sort By:
Page
of 27
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 24, 2014
A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma
Wolfgang Wick, Harald Fricke, Klaus Junge, et al.
Acta Neuropathologica
|
January 28, 2014
Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms
David E Reuss, Antje Habel, Christian Hagenlocher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2009
Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network
Michael Weller, Jörg Felsberg, Christian Hartmann, et al.
Neuro-Oncology
|
March 24, 2009
Characterization of novel and complex genomic aberrations in glioblastoma using a 32K BAC array
Helena Nord, Christian Hartmann, Robin Andersson, et al.
Neuro-Oncology
|
July 17, 2014
Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial
Benedikt Wiestler, David Capper, Volker Hovestadt, et al.
Cancer Research
|
April 3, 2003
Gene expression-based classification of malignant gliomas correlates better with survival than histological classification
Catherine L Nutt, D R Mani, Rebecca A Betensky, et al.
Clinical Neuropathology
|
March 31, 2023
Update on quality assurance in neuropathology: Summary of the round robin trials on <i>TERT</i> promoter mutation, <i>H3-3A</i> mutation, 1p/19q codeletion, and <i>KIAA1549::BRAF</i> fusion testing in Germany in 2020 and 2021
Sandra Pohl, Lora Dimitrova, Maja Grassow-Narlik, et al.
Acta Neuropathologica
|
May 13, 2015
IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO
David E Reuss, Yasin Mamatjan, Daniel Schrimpf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2009
Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival
Aurélie Ernst, Stefanie Hofmann, Rezvan Ahmadi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 11, 2009
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide
Wolfgang Wick, Christian Hartmann, Corinna Engel, et al.
Page
of 27